6,138 CVS Health Corporation $CVS Shares Purchased by State of Wyoming

State of Wyoming increased its holdings in CVS Health Corporation (NYSE:CVS) by 247.4% in the 3rd quarter, Holdings Channel reports. The fund owned 8,619 shares of the pharmacy operator’s stock after buying an additional 6,138 shares during the quarter. State of Wyoming’s holdings in CVS Health were worth $739,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of CVS. BlackRock Inc. bought a new stake in CVS Health during the second quarter worth about $12,747,462,000. State Street Corp increased its stake in shares of CVS Health by 26.3% during the second quarter. State Street Corp now owns 74,927,064 shares of the pharmacy operator’s stock valued at $7,751,205,000 after purchasing an additional 15,604,883 shares in the last quarter. Bank of America Corp DE increased its stake in shares of CVS Health by 148.0% during the second quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator’s stock valued at $2,398,868,000 after purchasing an additional 13,836,701 shares in the last quarter. Pzena Investment Management LLC bought a new position in shares of CVS Health during the second quarter valued at approximately $1,217,558,000. Finally, Wellington Management Group LLP lifted its holdings in shares of CVS Health by 49.8% during the second quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator’s stock valued at $3,496,725,000 after purchasing an additional 11,233,381 shares during the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: One valuation analysis estimates that CVS could be approximately 27% undervalued, citing its low valuation and expectations that upcoming earnings will clarify performance across its pharmacy, insurance and healthcare-services businesses. CVS Health Could Be 27% Undervalued
• Positive Sentiment: CVS is promoting free Project Health screenings that require no appointment or insurance. Although primarily a community-health initiative, the program may support customer engagement and the company’s broader healthcare strategy. CVS Project Health Screenings
• Neutral Sentiment: Wall Street is reportedly expecting about $1.62 in third-quarter earnings per share, with analysts examining metrics beyond revenue and EPS, including segment trends and operating performance. The results could provide an important catalyst after CVS’s previous quarterly earnings beat. CVS Q3 Earnings Estimates
• Neutral Sentiment: CVS is highlighting medication-safety education and substance-misuse prevention resources. The initiative strengthens its public-health positioning but is unlikely to materially affect near-term earnings. CVS Medication Safety Initiative
• Negative Sentiment: CVS faces a reported risk of roughly $2 billion related to Medicare Advantage star ratings. Lower ratings could reduce bonus payments and pressure profitability in its insurance business. CVS Medicare Ratings Risk
• Negative Sentiment: Six hospital systems, including the University of Kentucky, reportedly accuse CVS of fraud or contract breaches, with the Kentucky lawsuit seeking $41 million. Even if the claims are unresolved, additional litigation raises potential legal costs and reputational risk. Hospital Systems Sue CVS

CVS Health Stock Down 0.1%

Shares of CVS Health stock opened at $90.20 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. The stock has a market capitalization of $115.36 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 0.84 and a beta of 0.60. CVS Health Corporation has a 52-week low of $69.51 and a 52-week high of $110.68. The company has a 50-day simple moving average of $91.22 and a two-hundred day simple moving average of $88.76.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The firm had revenue of $106.10 billion for the quarter, compared to the consensus estimate of $100.03 billion. During the same quarter in the prior year, the firm posted $1.81 earnings per share. The business’s revenue was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, analysts anticipate that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Thursday, October 22nd will be issued a $0.6650 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Thursday, October 22nd. CVS Health’s payout ratio is presently 70.37%.

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of analyst reports. Sanford C. Bernstein reissued an “outperform” rating and issued a $112.00 price target on shares of CVS Health in a research report on Wednesday, September 9th. JPMorgan Chase & Co. raised their price objective on CVS Health from $111.00 to $118.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Wall Street Zen cut CVS Health from a “strong-buy” rating to a “buy” rating in a research note on Monday, October 19th. Royal Bank Of Canada boosted their target price on CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a report on Thursday, July 9th. Finally, BMO Capital Markets set a $112.00 target price on CVS Health in a research note on Wednesday, September 9th. Nineteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $109.64.

CVS Health Profile

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.